Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning how a drug moves into, through, and out of the body — in both children and adults. That’s according to data from the Phase 3 QUANTI Pediatric study (NCT05915026), which evaluated the safety and pharmacological properties…
Month: December 2025
Is this the end of PML? Treating JC virus with antivirals.
Tweet Everybody wants to get rid of EBV and there are a number of trials testing tenofovir alafenamide fumarate (TAF). This current study however reported that Tenofovir targets JC virus and so inhibits the development of PML. So this is good news. NDG treated PML in a different way but having an active antiviral iss…
Going from heat intolerance to cold sensitivity with MS
The heat has always been a part of my life in central Texas, whether I liked it or not. Every year, it seemed to linger for longer than most people would have liked. When I was diagnosed with relapsing-remitting multiple sclerosis, I realized the heat was definitely not my friend. At the beginning of my…
Time is Precious
By Angel Blair Time flies. You can say that again, and again, and again. It’s hard to believe that the end of 2025 is upon us and a new year is right around the corner. The year brought many changes, … Continue reading → Source: blog.mymsaa.org
Active lifestyles help support better mobility, mood in people with MS
Regular physical activity was independently linked to lower disability, fatigue, and depression over time in people with multiple sclerosis (MS), a new study found. Other lifestyle factors also supported better outcomes. For example, eating a higher-quality diet was independently associated with less disability, while not smoking was independently tied to lower depression scores, the data…
MS Patient Community Day draws record attendance from 89 nations
A few months ago in Barcelona, at the annual conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), thousands of participants from dozens of countries convened for Patient Community Day 2025 (PCD). This annual event brings together researchers focused on multiple sclerosis (MS) and associated demyelinating diseases, alongside people living with…
Is this one to Get ProfGs saliva going?
Tweet ProfG is on his crusade to target EBV….There are many ways to do this and one route is anti-virals and this is one example….Sounds interesting. Brincidofovir (BCV) is a broad-spectrum anti-viral agent and lipid-conjugate of cidofovir. The intracellular active form of BCV is known as CDV-PP (cidofovir diphosphate) and inhibits viral replication. I guess…
The methods for a failed trial
Tweet This a paper on the methods behind the remyelination trial that has been completed and preliminary results reported….so I am not really sure what the value is….surely one could wait and give the trial design and the results. These types of papers help you get the idea out, profK is busy doing ChariotMS and…
FDA gives tentative approval to generic Siponimod tablets for MS
The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS). Similar…
$1M grant funds study to prevent falls in older adults with MS
A Georgia State University researcher won a $1 million U.S. Department of Veterans Affairs (VA) grant to study whether a program combining cognitive training with exercise can help prevent falls in older adults with multiple sclerosis (MS). “Falls are so common — and frightening — in older adults,” Katherine Hsieh, PhD, an assistant professor of…